Non-interventional Post-Authorisation Safety Study of Burosumab in the Treatment of Children >1 year of age, Adolescents and Adults with X-Linked Hypophosphataemia (XLH PASS)

06/11/2019
19/05/2025
EU PAS number:
EUPAS32190
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

XLH Registry Protocol Amendment 2_Final_15Feb2019.pdf

English (878.72 KB - PDF) View document
Updated protocol

XLH Registry Protocol Amendment 3 with embedded PASS_27Oct2021_clean.pdf

First published: 15/05/2024
English (1.34 MB - PDF) View document
Study results
Study report
Other information
Study, other information

PASS Annual Progress Report 2019

English (133.59 KB - PDF) View document

PASS Annual Progress Report 2020

English (1.38 MB - PDF) View document

PASS Interim Study Report 4Oct2021

English (1.48 MB - PDF) View document

PASS Annual Progress Report 2022

English (198.31 KB - PDF) View document

PASS Annual Progress Report 2023

English (254.01 KB - PDF) View document

PASS Annual Progress Report 2024.pdf

English (283.98 KB - PDF) View document

PASS Annual Progress Report 2025.pdf

English (651.2 KB - PDF) View document